Please Wait...

HA // Hyaluronic Acid

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Hyaluronic acid (HA) is also known as hyaluronate or hyaluronan. This macromolecule is a ubiquitous linear polymer, especially abundant in connective tissues. HA is synthetized in the plasma membrane by a membrane-bound protein by addition of sugar units (D-glucuronic acid and D-N-acetylglucosamine, linked via alternating β-1,4 and β-1,3 glycosidic bonds) from a nucleotide precursor and followed by translocation to the extracellular space (Fraser et al., 1997). HA found in low concentration in blood comes from the peripheral tissues through the lymph and in physiological condition is rapidly took up and degraded by the liver. In patients with liver diseases, such as liver cirrhosis, increased serum levels of HA have been found. Increased blood levels can also be the result of inflammatory condition such as rheumatoid arthritis, psoriasis and scleroderma (Laurent and Fraser, 1992).

Bioclinica Lab employs a sandwich protein binding manual assay, which use Hyaluronic Acid Binding Protein for the capture and detection of HA. This assay is designed for the measurement of Collagen IV in serum.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t… https://t.co/kyQmz7FxlN
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain… https://t.co/UwVs6ajPp4
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen